3 Biotech Stocks with Potential Upside: Inovio Pharmaceuticals, Dynavax, and Ariad

Inovio, Dynavax, and Ariad are three biotech stocks that deserve a second look this year. Here’s why.

Feb 18, 2014 at 2:30PM

In a previous article, I discussed three fallen biotech stocks that were unlikely to bounce back anytime soon. In this article, I'll focus on three biotech stocks that could rally higher in 2014 -- Inovio Pharmaceuticals (NASDAQ:INO), Dynavax (NASDAQ:DVAX), and Ariad (NASDAQ:ARIA).

Inovio's big catalyst could be right around the corner
Inovio (NASDAQ:INO), which doesn't have any marketed products, has already soared more than 270% over the past 12 months on optimism regarding its pipeline.

INO Chart

Source: YCharts.

The company specializes in immunotherapy vaccines that target cancer, HPV, and other diseases by provoking an immune system response with synthetic DNA. The vaccines are delivered into the patient's body via Inovio's proprietary electroporation technology, which uses brief electrical pulses to boost cellular intake. Inovio (NASDAQ:INO) generates revenue from various grants, license fees, milestone payments, government contracts, and collaborative partners -- the largest of which is Swiss pharmaceutical giant Roche.

Inovio's (NASDAQ:INO) most advanced treatment, VGX-3100, has entered phase 2 trials as a therapeutic vaccine for cervical dysplasia, the leading cause of cervical cancer. VGX-3100 targets types 16 and 18 of the human papillomavirus (HPV), which has been implicated in 70% of cervical cancers. During a phase 1 proof-of-concept study of 18 women who had previously been treated for precancerous changes in the cervix, all 18 patients showed an immune response to the vaccine, while a T-cell response (which can kill off HPV-infected cells) was triggered in 14 patients.

If approved, VGX-3100 will compete directly against Merck's (NYSE:MRK) Gardasil and GlaxoSmithKline's Cervarix, and could generate $540 million in annual peak sales -- a huge boost for a company that has only reported $11.7 million in revenue in the first three quarters of 2013. However, that peak sales estimate is actually quite conservative, considering that Gardasil generated $1.83 billion in revenue during fiscal 2013. Cervarix, which trails Gardasil by a wide margin, only generated $270 million in revenue last year.

VGX-3100 could also be a more attractive new alternative to either Gardasil or Cervarix, considering that both vaccines are no longer recommended for girls ages 12 to 16 in Japan due to major safety concerns. Top line data from the phase 2 trial of VGX-3100, the next big catalyst for Inovio, is expected in the first half of this year.

Dynavax's big bet on Heplisav
Speaking of vaccines, Dynavax's (NASDAQ:DVAX) Heplisav, a hepatitis B vaccine, is also worth watching this year.

The vaccine has had a rocky history -- an FDA advisory committee recommended against its approval in November 2012 due to concerns about the use of a novel adjuvant, a TLR9 agonist, in the vaccine. Adjuvants are agents that enhance a vaccine so less foreign material has to be injected. The most commonly accepted novel adjuvant in vaccines is aluminum, which the FDA generally prefers over toll-like receptor agonists such as TLR9 and TLR4, which is used by GSK's Cervarix. The FDA then rejected Heplisav in February 2013, on grounds that more safety data was required for the 18 to 70 age group. The FDA was concerned that rare autoimmune conditions could develop in vaccinated patients.

The effect on Dynavax's (NASDAQ:DVAX) stock price was painfully clear:

DVAX Chart

Source: YCharts.

During two phase 3 trials, Heplisav was compared to GSK's Engerix-B. The first trial, HBV-10, consisted of 18- to 55-year-olds, and the second one, HBV-16, consisted of 40- to 70-year-olds. The trials showed that Heplisav was much more effective at achieving "seroprotection," which is defined as an anti-hepatitis B concentration of 10 mIU/mL or greater:





95.1% seroprotection

90% seroprotection


81.1% seroprotection

70.5% seroprotection

Source: Phase 3 data, industry websites.

However, one troublesome spot for Dynavax (NASDAQ:DVAX) was the development of ANCA vasculitis, a type of autoimmune swelling, in two patients in the HBV-10 trial -- one in the Heplisav arm and the other in the Engerix-B arm. The trial determined that the Heplisav case possibly caused the swelling, while the Engerix-B case was not related to the treatment. That smidgen of doubt was enough to cause the FDA to reject Heplisav and request additional safety data from Dynavax (NASDAQ:DVAX).

The good news is that Dynavax (NASDAQ:DVAX) hasn't given up. It issued a secondary offering last October to raise $125 million to fund HBV-23, a massive phase 3 trial consisting of 8,000 patients. By comparison, HBV-10 and HBV-16 consisted of 5,845 patients combined. Although that move initially wiped out shareholders, new investors shouldn't fear any additional offerings unless HBV-23 is unsuccessful. In addition, Dynavax's (NASDAQ:DVAX) collaborations with GSK and AstraZeneca will provide it with stable -- if limited -- revenue throughout the year.

If approved, Heplisav could generate peak sales of $775 million and compete directly against Engerix-B and Merck's Recombivax HB. At less than $2 per share, there's simply not much downside to Dynavax stock, although it has considerable upside potential on any positive updates about Heplisav.

Ariad deserves to go higher
Last but not least, Ariad (NASDAQ:ARIA) is a stock that has fallen on hard times in the last few months. The stock was crushed last October after the FDA pulled its leukemia drug Iclusig off the market due to safety concerns regarding cardiovascular events. Although the FDA allowed the drug back to the market last December with a new warning label, the stock still hasn't fully bounced back from those devastating losses:

ARIA Chart

Source: YCharts.

Iclusig treats two specific types of leukemia -- T315I positive chronic myeloid leukemia (CML) and T315I positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Due to the rarity of those types of leukemia, the FDA granted Iclusig an orphan drug status upon approval, which protects it from generic competition for seven years.

Iclusig has a wholesale price of $115,000 per patient per year, which is the model for the drug's peak sales projections of around $500 million per year -- a big boost for the company. It will be challenging for the drug to reach this lofty projection, and sales have been modest so far:


Iclusig Sales

Sequential Growth

1Q 2013

$6.4 million

N/A (launched January 2013)

2Q 2013

$13.9 million


3Q 2013

$16.7 million


Source: Ariad quarterly reports.

Shares of Ariad (NASDAQ:ARIA) could face more more pressure due to its dependence on Iclusig, but there could also be upside if the drug exceeds the market's expectations. Ariad (NASDAQ:ARIA) could also strike a partnership with a larger pharmaceutical partner such as Roche, it could be bought out by rumored interested parties such as Eli Lilly, GSK, and Shire, or it can sell lower doses of Iclusig as part of a combination therapy instead, boosting sales and allaying safety concerns at the same time.

The Foolish takeaway
In closing, there's no question that Inovio (NASDAQ:INO), Dynavax (NASDAQ:DVAX), and Ariad (NASDAQ:ARIA) are risky, speculative stocks. However, I believe that there is more upside than downside in all three stocks -- which makes them investments that biotech investors looking for riskier, higher-return stocks with visible catalysts down the road.

Even if Inovio, Dynavax, and Ariad have a great year, they could have trouble keeping up with this stock in 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Editor's Note: A previous version of this article was accidentally published before being edited. Small edits have been made to the headline and the section on Ariad Pharmaceuticals. The Fool regrets the error.

Leo Sun has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers